At a glance
ClinicalIndex Comparison RecordN/ACompleted· 86 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation
In Brief
An observational study for Secondary Hyperparathyroidism. Completed, enrolled 86 participants across 13 sites.
Detailed Summary
Eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in Russia. Planned therapy will be six months. Participants with Stage 5 Chronic Kidney Disease and with hyperparathyroidism on hemodialysis will be included into the study. Ability of Zemplar, (paricalcitol) to lower intact Parathyroid Hormone level will be assessed during the study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Hyperparathyroidism
CountriesRussia
CollaboratorsAlmedis
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionJan 2013
TodayJul 2026
First PostedJul 25, 2011
Enrollment StartJul 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.9 years ago